Scientists are now investigating a nonhormonal monthly ring (Ovaprene) as a potential contraceptive. The device involves a permeable mesh in the center of the ring that creates a partial barrier to sperm and locally acting spermiostatic agents to create an inhospitable environment for sperm.
Despite guidance stating that a patient should be offered the option to begin her chosen long-acting reversible contraception birth control method at the time of the office visit rather than waiting for her next period or returning for another appointment, just 29% of clinicians say they provide same-day placement.
Early studies of a potential male contraceptive pill, which contains a modified testosterone that has the combined actions of an androgen and a progesterone, are underway. The experimental male oral contraceptive was the subject of a recent study to analyze its safety, tolerability, pharmacokinetics, and pharmacodynamics.
The American College of Obstetricians and Gynecologists has released a practice bulletin to help providers use scientific evidence to guide women with coexisting medical conditions in making the most effective choices.
Family planning providers should develop ways to provide contraceptives to patients in one visit (known as Quick Start) for all methods, according to the Family Planning National Training Center’s Contraceptive Access Change Package. New research indicates that while most public-sector and private providers consider Quick Start for combined hormonal contraceptives and depot medroxyprogesterone acetate (DMPA) safe for use among adolescents, fewer private providers utilize the technique.